贝利尤单抗在系统性红斑狼疮患者中的长期安全性和有效性:美国一项76周III期母研究的延续研究
该美国多中心延续研究纳入完成76周III期试验的系统性红斑狼疮患者,继续接受贝利尤单抗或从安慰剂转为贝利尤单抗10 mg/kg联合标准治疗,评估长期安全性。结果显示治疗相关及严重不良事件发生率在研究第7年保持稳定或下降,第7年中点SRI应答率75.6%,确认了既往观察到的安全性和有效性特征。
要点
- 268例患者中140例完成研究、128例退出,基线SELENA-SLEDAI均值7.8。
- 研究第7年中点SRI应答率75.6%,78.2%患者SELENA-SLEDAI评分较基线降低≥4分。
- 研究第7年中点20.6%患者经历≥1次严重SFI flare,泼尼松剂量平均降低31.4%。
核心结论
- 这些长期暴露结果确认了贝利尤单抗在系统性红斑狼疮患者中既往观察到的安全性和有效性特征。
研究设计与样本
- 美国多中心延续研究(葛兰素史克研究BEL112233;ClinicalTrials.gov标识NCT00724867),纳入完成SLE贝利尤单抗76周试验(NCT00410384)的系统性红斑狼疮患者。
- 患者继续接受相同剂量贝利尤单抗联合标准治疗;既往接受安慰剂者改为贝利尤单抗10 mg/kg。
- 主要结局为贝利尤单抗长期安全性,包括不良事件频率及每48周(1个研究年)用SDI评估的损伤。
主要发现
- 268例患者中140例完成研究、128例退出;基线SELENA-SLEDAI均值±标准差为7.8±3.86。
- SDI评分较基线(1.2±1.51)平均±标准差增加0.4±0.68。
- 治疗相关及严重不良事件总体发生率在研究第7年保持稳定或下降。
- 研究第1年与第7年中点SRI应答率分别为41.9%与75.6%。
- 第7年中点较基线:78.2%患者SELENA-SLEDAI评分降低≥4分,98.4%无新发BILAG A器官域评分且新发BILAG B器官域评分不超过1个,93.7%医生整体评估无恶化,20.6%经历≥1次严重SFI flare,泼尼松剂量平均降低31.4%,CD20+ B细胞数中位变化为-83.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We undertook this US multicenter continuation study (GlaxoSmithKline study BEL112233; ClinicalTrials.gov identifier: NCT00724867) to assess long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) who completed the Study of Belimumab in Subjects with SLE 76-week trial (ClinicalTrials.gov identifier: NCT00410384). METHODS: Patients continued to receive the same belimumab dose plus standard therapy; patients previously receiving placebo received 10 mg/kg belimumab. The primary outcome measure was long-term safety of belimumab (frequency of adverse events [AEs] and damage assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI], evaluated every 48 weeks [1 study year]). Other assessments included the SLE Responder Index (SRI), flare rates (using the modified SLE Flare Index [SFI]), prednisone use, and B cell levels. RESULTS: Of 268 patients, 140 completed the study and 128 withdrew. The mean ± SD score on the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI) at baseline was 7.8 ± 3.86. The mean ± SD SDI score increased by 0.4 ± 0.68 from its value at baseline (1.2 ± 1.51). The overall incidence of treatment-related and serious AEs remained stable or declined through study year 7. An SRI response was achieved by 41.9% and 75.6% of patients at the study year 1 and study year 7 midpoints, respectively. At the study year 7 midpoint, relative to baseline, 78.2% had achieved a ≥4-point reduction in the SELENA-SLEDAI score, 98.4% had no new British Isles Lupus Assessment Group (BILAG) A organ domain score and no more than 1 new BILAG B organ domain score, 93.7% had no worsening in the physician's global assessment of disease activity, 20.6% had experienced ≥1 severe SFI flare, the mean decrease in prednisone dose was 31.4%, and the median change in CD20+ B cell numbers was -83.2%. CONCLUSION: These long-term exposure results confirm the previously observed safety and efficacy profiles of belimumab in patients with SLE.
引用
- Furie RA, Wallace DJ, Aranow C, et al. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol. 2018. PMID: 29409143. doi:10.1002/art.40439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。